P3
Progeny 3, Inc.
13F filer · CIK 0001536006Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$1.94BU.S. long equity reported on 13F
Positions271 new · 4 closed
Net flow last quarter+$13MBuys minus sells
Top 10 positions weight58.1%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202627 positions | |||||
| $241M | 12.44% | 0.54% | +0.9% | Q3 2018 | |
| $191M | 9.86% | 0.86% | Not reported | Q3 2024 | |
| $150M | 7.74% | 0.82% | Not reported | Q3 2022 | |
| $126M | 6.50% | 7.11% | +1.6% | Q1 2025 | |
| $82.7M | 4.27% | 0.57% | +5.9% | Q4 2023 | |
| $77.9M | 4.02% | 2.52% | +0.6% | Q4 2021 | |
| $65.3M | 3.37% | 0.19% | Not reported | Q1 2025 | |
| $64.8M | 3.34% | 0.46% | Not reported | Q4 2025 | |
| $64.5M | 3.33% | 0.00% | +8.2% | Q1 2020 | |
| $62M | 3.20% | 0.08% | +0.2% | Q3 2014 | |
| $58M | 2.99% | 0.74% | +92.9% | Q1 2026 | |
| $57.2M | 2.95% | 0.10% | Not reported | Q3 2019 | |
| $53.7M | 2.77% | 5.69% | Not reported | Q1 2024 | |
| $53.7M | 2.77% | 0.16% | Not reported | Q4 2023 | |
| $53.2M | 2.74% | 0.88% | Not reported | Q3 2025 | |
| $52.5M | 2.71% | 0.08% | Not reported | Q3 2019 | |
| $44.2M | 2.28% | 0.06% | Not reported | Q2 2024 | |
| $42.5M | 2.19% | 2.60% | Not reported | Q2 2020 | |
| $42.4M | 2.19% | 0.59% | New | Q2 2026 | |
| $41.2M | 2.13% | 0.31% | Not reported | Q3 2022 | |
| $37M | 1.91% | 5.14% | -2.2% | Q1 2022 | |
| $29.2M | 1.51% | 0.80% | +77.3% | Q1 2026 | |
| $26.6M | 1.37% | Not reported | Not reported | Q2 2020 | |
| $22.3M | 1.15% | 1.73% | -26.6% | Q4 2024 | |
| $18.3M | 0.94% | 0.33% | Not reported | Q4 2024 | |
| $4.4M | 0.23% | 0.10% | Not reported | Q3 2021 | |
| $1.39M | 0.07% | 0.01% | Not reported | Q4 2025 | |
| Q1 2026Reported May 15, 202630 positions | |||||
| $255M | 13.63% | 0.54% | Not reported | Q3 2018 | |
| $147M | 7.88% | 0.86% | +3.1% | Q3 2024 | |
| $143M | 7.67% | 0.82% | Not reported | Q3 2022 | |
| $101M | 5.39% | 6.93% | +0.6% | Q1 2025 | |
| $89.3M | 4.78% | 2.51% | -1.6% | Q4 2021 | |
| $85.1M | 4.55% | 0.52% | +11.9% | Q4 2023 | |
| $80.8M | 4.32% | Not reported | -5.1% | Q1 2024 | |
| $66.6M | 3.56% | 0.19% | Not reported | Q1 2025 | |
| $64.2M | 3.44% | 0.16% | +3.9% | Q4 2023 | |
| $63.7M | 3.41% | 0.08% | -3.6% | Q3 2014 | |
| $58M | 3.10% | 0.10% | -4.1% | Q3 2019 | |
| $57.8M | 3.09% | 0.06% | Not reported | Q2 2024 | |
| $55.7M | 2.98% | 0.46% | Not reported | Q4 2025 | |
| $53.7M | 2.87% | 5.69% | Not reported | Q1 2024 | |
| $53M | 2.83% | 0.08% | -4.6% | Q3 2019 | |
| $52.1M | 2.79% | 0.00% | Not reported | Q1 2020 | |
| $45.5M | 2.43% | 2.61% | Not reported | Q2 2020 | |
| $41M | 2.19% | 0.88% | +18.5% | Q3 2025 | |
| $40.1M | 2.14% | 0.31% | Not reported | Q3 2022 | |
| $37.8M | 2.02% | 2.36% | Not reported | Q4 2024 | |
| $28.9M | 1.55% | 5.26% | +5.6% | Q1 2022 | |
| $28.3M | 1.51% | 0.38% | New | Q1 2026 | |
| $25.5M | 1.36% | Not reported | Not reported | Q2 2020 | |
| $18.3M | 0.98% | 0.33% | Not reported | Q4 2024 | |
| $15.5M | 0.83% | 0.45% | New | Q1 2026 | |
| $5.05M | 0.27% | 0.10% | Not reported | Q3 2021 | |
| $1.36M | 0.07% | 0.02% | Not reported | Q3 2025 | |
| $1.35M | 0.07% | 0.02% | Not reported | Q4 2025 | |
| $1.2M | 0.06% | 0.01% | Not reported | Q4 2025 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $872K | 0.05% | 0.02% | Not reported | Q4 2025 |
| Q4 2025Reported Feb 17, 202635 positions | |||||
| $215M | 11.56% | 0.54% | -3.9% | Q3 2018 | |
| $154M | 8.29% | 6.91% | -0.2% | Q1 2025 | |
| $137M | 7.37% | 0.83% | +0.2% | Q3 2024 | |
| $135M | 7.29% | 0.85% | Not reported | Q3 2022 | |
| $98.4M | 5.30% | 0.47% | Not reported | Q4 2023 | |
| $87.7M | 4.72% | Not reported | +4.5% | Q1 2024 | |
| $76.3M | 4.10% | 2.56% | +0.3% | Q4 2021 | |
| $74.6M | 4.02% | 5.06% | +18.7% | Q1 2022 | |
| $70.5M | 3.79% | 0.19% | Not reported | Q1 2025 | |
| $56.5M | 3.04% | 0.10% | -2.2% | Q3 2019 | |
| $56M | 3.02% | 0.08% | -7.8% | Q3 2014 | |
| $54.3M | 2.92% | 5.63% | Not reported | Q1 2024 | |
| $53.8M | 2.90% | 2.61% | Not reported | Q2 2020 | |
| $52.1M | 2.80% | 0.16% | +38.8% | Q4 2023 | |
| $48.3M | 2.60% | 0.06% | Not reported | Q2 2024 | |
| $47.4M | 2.55% | 0.08% | +2.7% | Q3 2019 | |
| $45M | 2.42% | 0.31% | +4.7% | Q3 2022 | |
| $35.5M | 1.91% | 0.46% | New | Q4 2025 | |
| $32.6M | 1.76% | 2.38% | Not reported | Q4 2024 | |
| $32.4M | 1.75% | 0.19% | Not reported | Q3 2025 | |
| $28.2M | 1.52% | 0.75% | Not reported | Q3 2025 | |
| $26.8M | 1.44% | Not reported | Not reported | Q2 2020 | |
| $24.4M | 1.32% | 1.01% | +72.1% | Q3 2024 | |
| $20.3M | 1.09% | 0.33% | Not reported | Q4 2024 | |
| $14.8M | 0.80% | Not reported | Not reported | Q3 2025 | |
| $4.78M | 0.26% | 0.10% | Not reported | Q3 2021 | |
| $3.07M | 0.17% | 0.06% | +22.2% | Q3 2025 | |
| $3.05M | 0.16% | 0.03% | +22.8% | Q3 2025 | |
| $2.65M | 0.14% | 0.07% | -90.2% | Q1 2021 | |
| $1.65M | 0.09% | 0.02% | Not reported | Q3 2025 | |
| $1.18M | 0.06% | 0.10% | +54.0% | Q4 2024 | |
| CPCRNXCrinetics Pharmaceuticals, Inc. | $1.12M | 0.06% | 0.03% | New | Q4 2025 |
| $1.12M | 0.06% | 0.01% | New | Q4 2025 | |
| $1.08M | 0.06% | 0.02% | New | Q4 2025 | |
| $1.05M | 0.06% | 0.01% | New | Q4 2025 | |
| Q3 2025Reported Nov 14, 202532 positions | |||||
| $205M | 10.57% | 0.56% | Not reported | Q3 2018 | |
| $203M | 10.47% | 7.55% | +1.7% | Q1 2025 | |
| $146M | 7.55% | 0.83% | Not reported | Q3 2024 | |
| $122M | 6.28% | 0.85% | 0.0% | Q3 2022 | |
| $99.9M | 5.15% | 0.46% | Not reported | Q4 2023 | |
| $92.6M | 4.77% | Not reported | +6.7% | Q1 2024 | |
| $82.8M | 4.27% | 2.55% | +6.9% | Q4 2021 | |
| $71.3M | 3.68% | 0.19% | Not reported | Q1 2025 | |
| $68.6M | 3.54% | 4.27% | +16.9% | Q1 2022 | |
| $59.3M | 3.06% | 0.09% | Not reported | Q3 2014 | |
| $57.5M | 2.96% | 5.66% | +3.6% | Q1 2024 | |
| $56.6M | 2.92% | 2.62% | Not reported | Q2 2020 | |
| $54.1M | 2.79% | 0.11% | +2.1% | Q3 2019 | |
| $50.6M | 2.61% | 0.90% | +9.7% | Q3 2024 | |
| $48.1M | 2.48% | 0.08% | +2.1% | Q3 2019 | |
| $48M | 2.48% | 0.06% | Not reported | Q2 2024 | |
| $43.4M | 2.24% | 0.30% | Not reported | Q3 2022 | |
| $38.1M | 1.97% | 0.11% | Not reported | Q4 2023 | |
| $36.8M | 1.90% | 0.19% | New | Q3 2025 | |
| $32.8M | 1.69% | 2.38% | +3.3% | Q4 2024 | |
| $28.4M | 1.46% | 0.19% | Not reported | Q2 2024 | |
| $27.8M | 1.44% | 0.75% | New | Q3 2025 | |
| $26.8M | 1.38% | Not reported | Not reported | Q2 2020 | |
| $24.1M | 1.24% | 0.75% | -76.8% | Q1 2021 | |
| $20.1M | 1.04% | 0.33% | Not reported | Q4 2024 | |
| $15.3M | 0.79% | 0.72% | Not reported | Q3 2024 | |
| $12.9M | 0.66% | Not reported | New | Q3 2025 | |
| $3.45M | 0.18% | 0.10% | Not reported | Q3 2021 | |
| $2.37M | 0.12% | 0.03% | New | Q3 2025 | |
| $2.34M | 0.12% | 0.05% | New | Q3 2025 | |
| $1.4M | 0.07% | 0.07% | Not reported | Q4 2024 | |
| $1.04M | 0.05% | 0.02% | New | Q3 2025 | |
Premium opens every quarter this fund has filed